Diffuse endocrine system, neuroendocrine tumors and immunity: What's new?

Neuroendocrinology

Volumn 95, Issue 4, 2012, Pages 267-276

  Ameri, Pietro ^a   Ferone, Diego ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Cortistatin; Immunity; Neuroendocrine tumors; Neuropeptides; Somatostatin

Indexed keywords

CORTISTATIN; NEUROPEPTIDE; SOMATOSTATIN;

ADAPTIVE IMMUNITY; CROHN DISEASE; IMMUNE RESPONSE; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS;

ANIMALS; ENDOCRINE GLAND NEOPLASMS; ENDOCRINE SYSTEM; ENDOCRINOLOGY; HUMANS; IMMUNITY; MODELS, BIOLOGICAL; NEUROENDOCRINE TUMORS; NEUROPEPTIDES; SOMATOSTATIN;

EID: 84862754168     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000334612     Document Type: Review

References (76)

1. Montuenga LM, Guembe L, Burrell MA, Bodegas ME, Calvo A, Sola JJ, Sesma P, Villaro AC: The diffuse endocrine system: from embryogenesis to carcinogenesis. Prog Histochem Cytochem 2003;38:155-272.
2. Rindi G, Leiter AB, Kopin AS, Bordi C, Solcia E: The 'normal' endocrine cell of the gut: changing concepts and new evidences. Ann NY Acad Sci 2004;1014:1-12.
3. Chaplin DD: Overview of the immune response. J Allergy Clin Immunol 2010;125(suppl 2):S3-S23.
4. Ferone D, van Hagen PM, Pivonello R, Colao A, Lamberts SW, Hofland LJ: Physiological and pathophysiological role of somatostatin receptors in the human thymus. Eur J Endocrinol 2000;143(suppl 1):S27-S34.
5. ten Bokum AM, Hofland LJ, de Jong G, Bouma J, Melief MJ, Kwekkeboom DJ, Schonbrunn A, Mooy CM, Laman JD, Lamberts SW, van Hagen PM: Immunohistochemical localization of somatostatin receptor sst2A in sarcoid granulomas. Eur J Clin Invest 1999;29:630-636.
6. Ferone D, Pivonello R, Van Hagen PM, Dalm VA, Lichtenauer-Kaligis EG, Waaijers M, Van Koetsveld PM, Mooy DM, Colao A, Minuto F, Lamberts SW, Hofland LJ: Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. Am J Physiol Endocrinol Metab 2002;283:E1056-E1066.
7. Dalm VA, van Hagen PM, van Koetsveld PM, Achilefu S, Houtsmuller AB, Pols DH, van der Lely AJ, Lamberts SW, Hofland LJ: Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. Am J Physiol Endocrinol Metab 2003;285:E344-E353.
8. Lichtenauer-Kaligis EG, Dalm VA, Oomen SP, Mooij DM, van Hagen PM, Lamberts SW, Hofland LJ: Differential expression of somatostatin receptor subtypes in human peripheral blood mononuclear cell subsets. Eur J Endocrinol 2004;150:565-577.
9. Armani C, Catalani E, Balbarini A, Bagnoli P, Cervia D: Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages. J Leukoc Biol 2007;81:845-855.
10. Taniyama Y, Suzuki T, Mikami Y, Moriya T, Satomi S, Sasano H: Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J 2005;52:605-611.
11. Hagströmer L, Emtestam L, Stridsberg M, Talme T: Expression pattern of somatostatin receptor subtypes 1-5 in human skin: an immunohistochemical study of healthy subjects and patients with psoriasis or atopic dermatitis. Exp Dermatol 2006;15:950-957.
12. Ferone D, Pivonello R, Kwekkeboom DJ, Gatto F, Ameri P, Colao A, de Krijger RR, Minuto F, Lamberts SW, van Hagen PM, Hofland LJ: Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: implications for the in vivo visualization during somatostatin receptor scintigraphy. J Endocrinol Invest 2011, Epub ahead of print.
13. Ameri P, Gatto F, Arvigo M, Villa G, Resmini E, Minuto F, Murialdo G, Ferone D: Somatostatin receptor scintigraphy in thoracic diseases. J Endocrinol Invest 2007;30:889-902.
14. Pintér E, Helyes Z, Szolcsányi J: Inhibitory effect of somatostatin on inflammation and nociception. Pharmacol Ther 2006;112:440-456.
15. Bánvölgyi A, Pozsgai G, Brain SD, Helyes ZS, Szolcsányi J, Ghosh M, Melegh B, Pintér E: Mustard oil induces a transient receptor potential vanilloid 1 receptor-independent neurogenic inflammation and a non-neurogenic cellular inflammatory component in mice. Neuroscience 2004;125:449-459.
16. Ustinova EE, Gutkin DW, Pezzone MA: Sensitization of pelvic nerve afferents and mast cell infiltration in the urinary bladder following chronic colonic irritation is mediated by neuropeptides. Am J Physiol Renal Physiol 2007;292:F123-F130.
17. Helyes Z, Elekes K, Sándor K, Szitter I, Kereskai L, Pintér E, Kemény A, Szolcsányi J, McLaughlin L, Vasiliou S, Kipar A, Zimmer A, Hunt SP, Stewart JP, Quinn JP: Involvement of preprotachykinin A gene-encoded peptides and the neurokinin 1 receptor in endotoxin-induced murine airway inflammation. Neuropeptides 2010;44:399-406.
18. Razavi R, Chan Y, Afifiyan FN, Liu XJ, Wan X, Yantha J, Tsui H, Tang L, Tsai S, Santamaria P, Driver JP, Serreze D, Salter MW, Dosch HM: TRPV1+ sensory neurons control beta cell stress and islet inflammation in autoimmune diabetes. Cell 2006;127:1123-1135.
19. Helyes Z, Elekes K, Németh J, Pozsgai G, Sándor K, Kereskai L, Börzsei R, Pintér E, Szabó A, Szolcsányi J: Role of transient receptor potential vanilloid 1 receptors in endotoxin-induced airway inflammation in the mouse. Am J Physiol Lung Cell Mol Physiol 2007;292:L1173-L1181.
20. Helyes Z, Pintér E, Németh J, Sándor K, Elekes K, Szabó A, Pozsgai G, Keszthelyi D, Kereskai L, Engström M, Wurster S, Szolcsányi J: Effects of the somatostatin receptor subtype 4 selective agonist J-2156 on sensory neuropeptide release and inflammatory reactions in rodents. Br J Pharmacol 2006;149:405-415.
21. Varecza Z, Elekes K, László T, Perkecz A, Pintér E, Sándor Z, Szolcsányi J, Keszthelyi D, Szabó A, Sándor K, Molnár TF, Szántó Z, Pongrácz JE, Helyes Z: Expression of the somatostatin receptor subtype 4 in intact and inflamed pulmonary tissues. J Histochem Cytochem 2009;57:1127-1137.
22. Chowers Y, Cahalon L, Lahav M, Schor H, Tal R, Bar-Meir S, Levite M: Somatostatin through its specific receptor inhibits spontaneous and TNF-alpha- and bacteria-induced IL-8 and IL-1 beta secretion from intestinal epithelial cells. J Immunol 2000;165:2955-2961.
23. Karalis K, Mastorakos G, Sano H, Wilder RL, Chrousos GP: Somatostatin may participate in the antiinflammatory actions of glucocorticoids. Endocrinology 1995;136:4133-4138.
24. Helyes Z, Pintér E, Sándor K, Elekes K, Bánvölgyi A, Keszthelyi D, Szoke E, Tóth DM, Sándor Z, Kereskai L, Pozsgai G, Allen JP, Emson PC, Markovics A, Szolcsányi J: Impaired defense mechanism against inflammation, hyperalgesia, and airway hyperreactivity in somatostatin 4 receptor gene-deleted mice. Proc Natl Acad Sci USA 2009;106:13088-13093.
25. Van Op den Bosch J, Torfs P, De Winter BY, De Man JG, Pelckmans PA, Van Marck E, Grundy D, Van Nassauw L, Timmermans JP: Effect of genetic SSTR4 ablation on inflammatory peptide and receptor expression in the non-inflamed and inflamed murine intestine. J Cell Mol Med 2009;13:3283-3295.
26. Siehler S, Nunn C, Hannon J, Feuerbach D, Hoyer D: Pharmacological profile of somatostatin and cortistatin receptors. Mol Cell Endocrinol 2008;286:26-34.
27. Robas N, Mead E, Fidock M: MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion. J Biol Chem 2003;278:44400-44404.
28. Gonzalez-Rey E, Chorny A, Robledo G, Delgado M: Cortistatin, a new antiinflammatory peptide with therapeutic effect on lethal endotoxemia. J Exp Med 2006;203:563-571.
29. Gonzalez-Rey E, Varela N, Sheibanie AF, Chorny A, Ganea D, Delgado M: Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease. Proc Natl Acad Sci USA 2006;103:4228-4233.
30. Gonzalez-Rey E, Chorny A, Del Moral RG, Varela N, Delgado M: Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and Th1 responses. Ann Rheum Dis 2007;66:582-588.
31. Dello Russo C, Lisi L, Navarra P, Tringali G: Diverging effects of cortistatin and somatostatin on the production and release of prostanoids from rat cortical microglia and astrocytes. J Neuroimmunol 2009;213:78-83.
32. Gonzalez-Rey E, Chorny A, Delgado M: Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat Rev Immunol 2007;7:52-63.
33. Gonzalez-Rey E, Delgado M: Vasoactive intestinal peptide inhibits cyclooxygenase-2 expression in activated macrophages, microglia, and dendritic cells. Brain Behav Immun 2008;22:35-41.
34. Chorny A, Delgado M: Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. Am J Pathol 2008;172:1297-1307.
35. Chorny A, Anderson P, Gonzalez-Rey E, Delgado M: Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. J Immunol 2008;180:8369-8377.
36. Gonzalez-Rey E, Ganea D, Delgado M: Neuropeptides: keeping the balance between pathogen immunity and immune tolerance. Curr Opin Pharmacol 2010;10:473-481.
37. Suto B, Bagoly T, Borzsei R, Lengl O, Szolcsanyi J, Nemeth T, Loibl C, Bardonicsek Z, Pinter E, Helyes Z: Surgery and sepsis increase somatostatin-like immunoreactivity in the human plasma. Peptides 2010;31:1208-1212.
38. Sciola V, Massironi S, Conte D, Caprioli F, Ferrero S, Ciafardini C, Peracchi M, Bardella MT, Piodi L: Plasma chromogranin A in patients with inflammatory bowel disease. Inflamm Bowel Dis 2009;15:867-871.
39. Capellino S, Lowin T, Angele P, Falk W, Grifka J, Straub RH: Increased chromogranin A levels indicate sympathetic hyperactivity in patients with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 2008;35:91-99.
40. Sørhaug S, Langhammer A, Waldum HL, Hveem K, Steinshamn S: Increased serum levels of chromogranin A in male smokers with airway obstruction. Eur Respir J 2006;28542-28548.
41. Di Comite G, Marinosci A, Di Matteo P, Manfredi A, Rovere-Querini P, Baldissera E, Aiello P, Corti A, Sabbadini MG: Neuroendocrine modulation induced by selective blockade of TNF-alpha in rheumatoid arthritis. Ann NY Acad Sci 2006;1069:428-437.
42. Di Comite G, Rossi CM, Marinosci A, Lolmede K, Baldissera E, Aiello P, Mueller RB, Herrmann M, Voll RE, Rovere-Querini P, Sabbadini MG, Corti A, Manfredi AA: Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-alpha-elicited endothelial activation. J Leukoc Biol 2009;85:81-87.
43. Levite M: Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype. Proc Natl Acad Sci USA 1998;95:12544-12549.
44. Weinstock JV, Elliott D: The somatostatin immunoregulatory circuit present at sites of chronic inflammation. Eur J Endocrinol 2000;143(suppl 1):S15-S19.
45. Herberth G, Daegelmann C, Weber A, Röder S, Giese T, Krämer U, Schins RP, Behrendt H, Borte M, Lehmann I; LISAplus Study Group: Association of neuropeptides with Th1/Th2 balance and allergic sensitization in children. Clin Exp Allergy 2006;36:1408-1416.
46. Brod SA, Hood ZM: Ingested (oral) SST inhibits EAE. Autoimmunity 2011;44:437-443.
47. Wing K, Sakaguchi S: Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010;11:7-13.
48. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-336.
49. Yamagiwa S, Gray JD, Hashimoto S, Horwitz DA: A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J Immunol 2001;166:7282-7289.
50. Anderson P, Gonzalez-Rey E: Vasoactive intestinal peptide induces cell cycle arrest and regulatory functions in human T cells at multiple levels. Mol Cell Biol 2010;30:2537-2551.
51. Prasse A, Zissel G, Lützen N, Schupp J, Schmiedlin R, Gonzalez-Rey E, Rensing-Ehl A, Bacher G, Cavalli V, Bevec D, Delgado M, Müller-Quernheim J: Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med 2010;182:540-548.
52. Pozo D, Anderson P, Gonzalez-Rey E: Induction of alloantigen-specific human T regulatory cells by vasoactive intestinal peptide. J Immunol 2009;183:4346-4359.
53. Wang J, Zhao R, Zhang F, Li J, Huo B, Cao Y, Dou K: Control of allograft rejection in mice by applying a novel neuropeptide, cortistatin. Adv Ther 2008;25:1331-1341.
54. Mignini F, Sabbatini M, D'Andrea V, Cavallotti C: Neuropeptides of human thymus in normal and pathological conditions. Peptides DOI:10.1016/j.peptides. 2011.01.022.
55. Amantini C, Mosca M, Lucciarini R, Perfumi MC, Santoni G: Thiorphan-induced survival and proliferation of rat thymocytes by activation of Akt/survivin pathway and inhibition of caspase-3 activity. J Pharmacol Exp Ther 2008;327:215-225.
56. Schott M: Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers. Endocr Relat Cancer 2006;13:779-795.
57. Wuttke M, Papewalis C, Jacobs B, Schott M: Identifying tumor antigens in endocrine malignancies. Trends Endocrinol Metab 2009;20:122-129.
58. Oberg K, Ferone D, Kaltsas G, Knigge UP, Taal B, Plöckinger U; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy. Neuroendocrinology 2009;90:209-213.
59. Vitale G, van Koetsveld PM, de Herder WW, van der Wansem K, Janssen JA, Colao A, Lombardi G, Lamberts SW, Hofland LJ: Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells. Am J Physiol Endocrinol Metab 2009;296:E559-E566.
60. Erdos M, Garami M, Rákóczi E, Zalatnai A, Steinbach D, Baumann U, Kropshofer G, Tóth B, Maródi L: Neuroendocrine carcinoma associated with X-linked hyper-immunoglobulin M syndrome: report of four cases and review of the literature. Clin Immunol 2008;129:455-461.
61. Ryschich E, Autschbach F, Eisold S, Klar E, Buchler MW, Schmidt J: Expression of HLA class I/II antigens and T cell immune response in human neuroendocrine tumors of the pancreas. Tissue Antigens 2003;62:48-54.
62. Vikman S, Sommaggio R, De La Torre M, Oberg K, Essand M, Giandomenico V, Loskog A, Totterman TH: Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue. Acta Oncol 2009;48:391-400.
63. Katz SC, Donkor C, Glasgow K, Pillarisetty VG, Gönen M, Espat NJ, Klimstra DS, D'Angelica MI, Allen PJ, Jarnagin W, Dematteo RP, Brennan MF, Tang LH: T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases. HPB (Oxford) 2010;12:674-683.
64. Vikman S, Essand M, Cunningham JL, de la Torre M, Oberg K, Tötterman TH, Giandomenico V: Gene expression in midgut carcinoid tumors: potential targets for immunotherapy. Acta Oncol 2005;44:32-40.
65. Vikman S, Giandomenico V, Sommaggio R, Oberg K, Essand M, Tötterman TH: CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients. Cancer Immunol Immunother 2008;57:399-409.
66. Papewalis C, Jacobs B, Wuttke M, Ullrich E, Baehring T, Fenk R, Willenberg HS, Schinner S, Cohnen M, Seissler J, Zacharowski K, Scherbaum WA, Schott M: IFN-alpha skews monocytes into CD56+-expressing dendritic cells with potent functional activities in vitro and in vivo. J Immunol 2008;180:1462-1470.
67. Papewalis C, Jacobs B, Baran AM, Ehlers M, Stoecklein NH, Willenberg HS, Schinner S, Anlauf M, Raffel A, Cupisti K, Fenk R, Scherbaum WA, Schott M: Increased numbers of tumor-lysing monocytes in cancer patients. Mol Cell Endocrinol 2011;337:52-61.
68. Katsenelson NS, Shurin GV, Bykovskaia SN, Shogan J, Shurin MR: Human small cell lung carcinoma and carcinoid tumor regulate dendritic cell maturation and function. Mod Pathol 2001;14:40-45.
69. Nishikawa H, Sakaguchi S: Regulatory T cells in tumor immunity. Int J Cancer 2010;127:759-767.
70. Beer TW, Ng LB, Murray K: Mast cells have prognostic value in Merkel cell carcinoma. Am J Dermatopathol 2008;30:27-30.
71. Schott M, Seissler J, Feldkamp J, von Schilling C, Scherbaum WA: Dendritic cell immunotherapy induces antitumour response in parathyroid carcinoma and neuroendocrine pancreas carcinoma. Horm Metab Res 1999;31:662-664.
72. Schott M, Seissler J, Lettmann M, Fouxon V, Scherbaum WA, Feldkamp J: Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J Clin Endocrinol Metab 2001;86:4965-4969.
73. Bachleitner-Hofmann T, Friedl J, Hassler M, Hayden H, Dubsky P, Sachet M, Rieder E, Pfragner R, Brostjan C, Riss S, Niederle B, Gnant M, Stift A: Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma. Oncol Rep 2009;21:1585-1592.
74. Papewalis C, Wuttke M, Seissler J, Meyer Y, Kessler C, Jacobs B, Ullrich E, Willenberg HS, Schinner S, Baehring T, Scherbaum WA, Schott M: Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer. Clin Cancer Res 2008;14:4298-4305.
75. Papewalis C, Kouatchoua C, Ehlers M, Jacobs B, Porwol D, Schinner S, Willenberg HS, Anlauf M, Raffel A, Eisenhofer G, Neumann HP, Bornstein SR, Scherbaum WA, Schott M: Chromogranin A as potential target for immunotherapy of malignant pheochromocytoma. Mol Cell Endocrinol 2011;335:69-77.
76. Abad C, Tan YV, Lopez R, Nobuta H, Dong H, Phan P, Feng JM, Campagnoni AT, Waschek JA: Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2010;107:19555-19560.